Clinical trials

  • Fluocinolone acetonide for Diabetic macular oedema
  • TINZAPARIN SODIUM for Epithelial ovarian cancer | Fallopian tube cancer | Primary peritoneal carcinoma
  • B/PHUKET/3073/2013 - LIKE STRAIN (B/PHUKET/3073/2013, MEDI 306444), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 - LIKE STRAIN (B/AUSTRIA/1359417/2021, MEDI 355292), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/NORWAY/16606/2021, MEDI 355293), INFLUENZA VIRUS A/VICTORIA/4897/2022 (H1N1)PDM09 - LIKE STRAIN (A/NORWAY/31694/2022, MEDI 369815) for Healthy individuals
  • lovotibeglogene autotemcel for Sickle cell disease
  • CISPLATIN for Squamous cell carcinoma of the larynx | Squamous cell carcinoma of the hypopharynx
  • NIVOLUMAB for Hepatocellular carcinoma | Intermediate-stage hepatocellular carcinoma
  • CISPLATIN for Malignant tumors of paranasal sinuses | Salivary gland carcinoma
  • GLUCOSE for Severe burns
  • SODIUM ZIRCONIUM CYCLOSILICATE for Chronic heart failure | Chronic kidney disease
  • TEZEPELUMAB for Chronic rhinosinusitis with nasal polyps
  • N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3-NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE for Chronic lymphocytic leukemia (previously untreated)
  • ENASIDENIB MESILATE for Myelodysplastic syndrome with IDH2 mutation